Financial Performance - Total revenue for the three months ended September 30, 2022, was RMB 93,214,000, an increase from RMB 26,872,000 in the same period of 2021[15]. - Profit before income tax for the three months ended September 30, 2022, was RMB 1,310,000, up from RMB 397,000 in the prior year[15]. - The profit and total comprehensive income for the period attributable to owners of the Company was RMB 930,000 for the three months ended September 30, 2022, compared to RMB 12,000 in the same period of 2021[15]. - Total revenue for the nine months ended September 30, 2022, was RMB 235,680,000, an increase from RMB 79,315,000 in the same period of 2021[15]. - The Group's total comprehensive income for the nine months ended September 30, 2022, was RMB 9,015,000, compared to RMB 4,424,000 in the prior year[15]. - Profit for the period after tax for the three months ended September 30, 2022, was RMB 230,000, compared to RMB 19,000 in the same period of 2021, reflecting a substantial increase[39]. - Profit attributable to owners of the Company for the Period was approximately RMB 9.0 million, up from RMB 3.9 million in the Prior Period, mainly due to increased income from trading of medical equipments[90]. Revenue Sources - Finance leasing income for the three months ended September 30, 2022, was RMB 11,295,000, slightly up from RMB 11,210,000 in the prior year[15]. - Income from postpartum care services and medical equipment trading reached RMB 16,204,000 for the three months ended September 30, 2022, compared to RMB 13,478,000 in the same period of 2021[15]. - The Group reported a significant increase in income from trading of medical equipment and consumables, reaching RMB 65,711,000 for the three months ended September 30, 2022[15]. - Revenue from finance leasing services during the nine months ended September 30, 2022, was RMB 31.1 million, serving approximately 4,000 SMEs across 30 provinces in China[61]. - Maternal and child postpartum care services generated revenue of RMB 40.9 million during the same period[63]. - The trading of medical equipment and consumables business achieved revenue of RMB 163.6 million during the nine months ended September 30, 2022[68]. Costs and Expenses - Interest on bank borrowing increased significantly to RMB 3,210,000 for the three months ended September 30, 2022, compared to RMB 1,949,000 in the same period of 2021, representing a 64.5% increase[36]. - Total staff costs for the three months ended September 30, 2022, were RMB 11,568,000, up 21.2% from RMB 9,545,000 in the same period of 2021[44]. - Cost of inventories sold surged to RMB 60,264,000 for the three months ended September 30, 2022, compared to RMB 1,909,000 in the same period of 2021, indicating a significant increase[44]. - Staff costs increased from RMB 25.3 million in the Prior Period to approximately RMB 31.2 million for the Period, primarily due to an increase in headcount and salaries[78]. - Other operating expenses rose from approximately RMB 38.2 million for the Prior Period to approximately RMB 41.9 million for the Period, mainly due to increased expenses in the postpartum care business[81]. - Finance costs increased from approximately RMB 6.0 million in the Prior Period to approximately RMB 9.7 million for the Period, driven by higher interest on bank and other borrowings[84]. Shareholder Information - As of September 30, 2022, Mr. Zhang Junshen and Mr. Zhang Junwei each hold 300,000,000 shares, representing a 75% interest in the Company[98][100]. - The ultimate controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, confirmed their concert party arrangement on February 24, 2017, acknowledging their joint interests[100]. - The Company has a total of 75% of its issued share capital deemed to be held by the controlling shareholders[100]. - Ms. Tang Yiping holds a spouse interest in 300,000,000 shares, also representing a 75% interest in the Company[120]. Corporate Governance - The Company has complied with the GEM Listing Rules regarding the disclosure of interests and short positions[110]. - The Company has complied with the provisions of the Corporate Governance Code, except for a deviation from code provision A.2.1 regarding the separation of roles of chairman and CEO[135][140]. - The Audit Committee reviewed the unaudited condensed consolidated financial statements for the nine months ended September 30, 2022, confirming compliance with applicable accounting standards and GEM Listing Rules[147]. - The Company considers high standards of corporate governance essential for its continuous growth[135]. Future Outlook - The Group remains optimistic about sustaining core business despite economic uncertainties due to Covid-19, focusing on leveraging the current client base for growth[69]. - The Group plans to continue investing in various businesses to find opportunities amidst challenges, aiming to enhance corporate and social value[70]. - The healthcare industry is expected to become a new economic breakthrough post-pandemic, with significant value-added potential[69]. - The Group is strategically focusing on finance leasing services and medical equipment related to the oral cavity and maternity and child industry[69].
紫元元(08223) - 2022 Q3 - 季度财报